| Edoxaban versus warfarin in patients with atrial fibrillation RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ... New England Journal of Medicine 369 (22), 2093-2104, 2013 | 5803 | 2013 |
| How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and … WJ Paulus, C Tschöpe, JE Sanderson, C Rusconi, FA Flachskampf, ... European heart journal 28 (20), 2539-2550, 2007 | 3877 | 2007 |
| Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre … European Trial on Reduction of Cardiac Events with Perindopril in Stable ... The Lancet 362 (9386), 782-788, 2003 | 3035 | 2003 |
| The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial P Lechat, KW Brunhuber, R Hofmann, P Kuhn, HJ Nesser, J Slany, ... Lancet 353 (9146), 9-13, 1999 | 2428 | 1999 |
| Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised … Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with ... The Lancet 372 (9644), 1174-1183, 2008 | 1220 | 2008 |
| Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy … P Vranckx, M Valgimigli, P Jüni, C Hamm, PG Steg, D Heg, GA van Es, ... The Lancet 392 (10151), 940-949, 2018 | 689 | 2018 |
| Cardiomyocyte stiffness in diastolic heart failure A Borbély, J Van Der Velden, Z Papp, JGF Bronzwaer, I Edes, ... Circulation 111 (6), 774-781, 2005 | 681 | 2005 |
| Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain A Tóth, J Boczán, N Kedei, E Lizanecz, Z Bagi, Z Papp, I Édes, L Csiba, ... Molecular Brain Research 135 (1-2), 162-168, 2005 | 510 | 2005 |
| Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium A Borbély, I Falcao-Pires, L van Heerebeek, N Hamdani, I Edes, C Gavina, ... Circulation research 104 (6), 780-786, 2009 | 435 | 2009 |
| Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan Z Papp, I Édes, S Fruhwald, SG De Hert, M Salmenperä, H Leppikangas, ... International journal of cardiology 159 (2), 82-87, 2012 | 375 | 2012 |
| Thyroid hormone-induced alterations in phospholamban protein expression. Regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation. E Kiss, G Jakab, EG Kranias, I Edes Circulation research 75 (2), 245-251, 1994 | 364 | 1994 |
| Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data M Gyöngyösi, W Wojakowski, P Lemarchand, K Lunde, M Tendera, ... Circulation research 116 (8), 1346-1360, 2015 | 341 | 2015 |
| Effects of Levosimendan, a Cardiotonic Agent Targeted to Troponin C, on Cardiac Function and on Phosphorylation and Ca2+ Sensitivity of Cardiac Myofibrils and … I Edes, E Kiss, Y Kitada, FM Powers, JG Papp, EG Kranias, RJ Solaro Circulation research 77 (1), 107-113, 1995 | 302 | 1995 |
| Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo … HA Ghofrani, G Simonneau, AM D'Armini, P Fedullo, LS Howard, X Jaïs, ... The Lancet Respiratory Medicine 12 (4), e21-e30, 2024 | 292 | 2024 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 246 | 2019 |
| Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial J Bartunek, A Terzic, BA Davison, GS Filippatos, S Radovanovic, ... European heart journal 38 (9), 648-660, 2017 | 224 | 2017 |
| Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo … DL Bhatt, PG Steg, SR Mehta, LA Leiter, T Simon, K Fox, C Held, ... The Lancet 394 (10204), 1169-1180, 2019 | 200 | 2019 |
| The patient perspective: quality of life in advanced heart failure with frequent hospitalisations MS Nieminen, K Dickstein, C Fonseca, JM Serrano, J Parissis, F Fedele, ... International journal of cardiology 191, 256-264, 2015 | 197 | 2015 |
| Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial M Szarek, HD White, GG Schwartz, M Alings, DL Bhatt, VA Bittner, ... Journal of the American College of Cardiology 73 (4), 387-396, 2019 | 189 | 2019 |
| Pharmacological mechanisms contributing to the clinical efficacy of levosimendan Z Papp, K Csapó, P Pollesello, H Haikala, I Édes Cardiovascular drug reviews 23 (1), 71-98, 2005 | 184 | 2005 |
Zoltán PappUniversity of Debrecen, Department of Cardiology, Division of Clinical PhysiologyEmail verificata su med.unideb.hu
